- Board initiated formal strategic process.
TransCode Therapeutics has launched a formal strategic process to maximize value of its oncology portfolio, including lead candidate TTX-MC138. The company retained Tungsten Advisors as exclusive financial advisor. Options include licensing, partnerships, or a sale. TTX-MC138 is in Phase 2a for ctDNA-positive colorectal cancer. No assurance of a deal.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.